Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

D7071

Sigma-Aldrich

Dapoxetine hydrochloride

≥98% (HPLC)

Sinonimo/i:

(S)-N,N-dimethyl-1-phenyl-3-(1-naphthalenyloxy)propanamine hydrochloride, S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine hydrochloride, LY-210448 hydrochloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 MG
110,00 €
50 MG
430,00 €

110,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
10 MG
110,00 €
50 MG
430,00 €

About This Item

Formula empirica (notazione di Hill):
C21H23NO · HCl
Numero CAS:
Peso molecolare:
341.87
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

110,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

powder

Attività ottica

[α]/D +125 to +135°, c = 1 in methanol

Condizioni di stoccaggio

desiccated

Colore

white

Solubilità

DMSO: ≥20 mg/mL

Ideatore

Eli Lilly

Temperatura di conservazione

room temp

Stringa SMILE

Cl.CN(C)[C@@H](CCOc1cccc2ccccc12)c3ccccc3

InChI

1S/C21H23NO.ClH/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21;/h3-14,20H,15-16H2,1-2H3;1H/t20-;/m0./s1
IHWDIQRWYNMKFM-BDQAORGHSA-N

Informazioni sul gene

human ... SLC6A4(6532)

Descrizione generale

Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.[1]

Azioni biochim/fisiol

Dapoxetine is capable of blocking recombinant Kv4.3 potassium voltage-gated channels. It is considered as safe.[1]
Potent Selective serotonin reuptake inhibitor (SSRI); used in treatment of premature ejaculation
Potent and selective SSRI

Caratteristiche e vantaggi

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

W J G Hellstrom
International journal of clinical practice, 65(1), 16-26 (2010-12-16)
Current and upcoming treatment options for premature ejaculation (PE) are of global clinical interest. In 2008, the International Society for Sexual Medicine published an evidence-based definition for PE. While there are no US Food and Drug Administration-approved therapies for PE
Chris G McMahon et al.
The journal of sexual medicine, 8(2), 524-539 (2010-11-10)
Dapoxetine has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies in various populations worldwide and has recently been approved in several countries. To present integrated efficacy and safety data from phase 3 trials
Hartmut Porst
The journal of sexual medicine, 8 Suppl 4, 335-341 (2011-10-14)
With increasing interest and clinical research in male sexual disorders, it has become clear that not only psychological but also organic, neurobiological, and genetic factors may play an important role in premature ejaculation (PE). This article provides an overview of
Shiwei Tang et al.
Advances in therapy, 36(8), 2096-2105 (2019-05-31)
Factors that impact the pharmacokinetics of dapoxetine, a 5-HT selective reuptake inhibitor used for the treatment of premature ejaculation, have not been clearly identified. This study aimed to evaluate the effects of consumption of a high-fat meal and cytochrome P450
Nicola Mondaini et al.
Urology, 82(3), 620-624 (2013-08-31)
To assess both the acceptance and the discontinuation rates from dapoxetine, the first oral pharmacological agent indicated for the treatment of premature ejaculation (PE). One hundred twenty consecutive potent patients (mean age 40.3 years; range 18-63 years) seeking medical treatment

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.